Anna E Lokshin (Pittsburgh, PA / US), Randal Brand (Pittsburgh, PA / US), Denise Prosser (Pittsburgh, PA / US), Liudmila Velikokhatnaya (Pittsburgh, PA / US), Lynette Smith (Pittsburgh, PA / US)
Multiplexed bead-based immunoassay was used for development of biomarkers associated with resectable pancreatic ductal adenocarcinoma (PDAC). Seventy-eight candidate biomarkers were measured in urine samples from patients with resectable PDAC (rPDAC) (n=88) in comparison with healthy (n=46), benign pancreatic disease (n=41), and unresectable PDAC (urPDAC) (n=36). Following biomarkers were altered in rPDAC vs. non-PDAC (healthy+benign) with high statistically significance at p<0.001: bHCG, Thrombospondin-2, HGF MIF, VCAM1, LRG1, Cyfra21.1, NCAM, ICAM1, KIM1, IGFBP1, CathD, CalbD, ErbB2, Tie2, PAI1, suPAR, SCF, MCSF, IGFBP2, Fn, GDF15, AFP, HE4, PDGFAB/BB, RANTES, PEDF, CXCL10, IL-6, MMP2, EGFR. Only bHCG was statistically different between rPDAC vs urPDAC. Classification algorithm comprised of bHCG, CXCL10, PDGFAB/BB offered 90%SN for rPDAC at 50%SP for healthy+benign.